Pfizer (NYSE:PFE) Trading Down 1.7% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) shares fell 1.7% during trading on Thursday . The stock traded as low as $23.62 and last traded at $23.6350. 57,053,733 shares changed hands during mid-day trading, an increase of 35% from the average daily volume of 42,259,691 shares. The stock had previously closed at $24.04.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Pfizer’s Ibrance label for maintenance treatment in HR+, HER2+ advanced or metastatic breast cancer, creating a new approved use that could support future sales. FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
• Positive Sentiment: Pfizer’s board declared a $0.43 quarterly dividend, highlighting the company’s cash return policy and supporting the stock’s appeal for income-focused investors. Pfizer Declares Third-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer’s venture arm helped lead a $62 million Series B round for Oblenio Bio, signaling continued interest in external innovation but with limited near-term impact on earnings. Oblenio Bio Closes $62 Million Series B
• Neutral Sentiment: Pfizer’s CFO, David Denton, is leaving for Nike, a leadership change that matters strategically but is not a core operating catalyst. Nike Names Pfizer’s Denton as Next CFO
• Negative Sentiment: Pfizer’s Phase 3 lung cancer drug candidate failed to show a statistically significant overall survival benefit, renewing concerns about pipeline execution and weighing on shares. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Analyst Ratings Changes

Several equities analysts have recently issued reports on PFE shares. Guggenheim lifted their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Morgan Stanley raised their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Tuesday. Finally, CICC Research started coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Down 1.7%

The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average price of $26.07 and a 200-day moving average price of $26.31. The stock has a market capitalization of $134.71 billion, a P/E ratio of 18.04 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently made changes to their positions in PFE. Horizon Financial Services LLC grew its position in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC increased its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. lifted its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.